Does Rallies show 13F holders for PFE?

Yes. Rallies tracks hedge fund and 13F ownership data for PFE, including fund names, share counts, latest tracked quarter, and position changes when available.

Is PFE research on Rallies investment advice?

No. Rallies provides research, data, and educational context for PFE. It does not provide personalized investment advice.

PFE (Pfizer) Stock Analysis - Hedge Fund Holdings

Pfizer (PFE) is a publicly traded Healthcare sector company. As of May 20, 2026, PFE trades at $25.78 with a market cap of $144.37B and a P/E ratio of 19.70. PFE moved +0.47% today. Year to date, PFE is +1.91%; over the trailing twelve months it is +11.57%. Its 52-week range spans $20.92 to $30.43. Analyst consensus is neutral with an average price target of $29.17. Rallies surfaces PFE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns PFE stock?

Hedge funds tracked by Rallies that own PFE include Starboard Value, D1 Capital, Orbimed Advisors, Bridgewater Associates, and Fairfax Financial. The latest tracked quarter is Jun 30, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Pfizer.

PFE Key Metrics

Key financial metrics for PFE
Metric	Value
Price	$25.78
Market Cap	$144.37B
P/E Ratio	19.70
EPS	$1.31
Dividend Yield	0.43%
52-Week High	$30.43
52-Week Low	$20.92
Volume	29.35M
Avg Volume	0
Revenue (TTM)	$63.31B
Net Income	$7.53B
Gross Margin	73.51%

Top Hedge Funds Holding PFE

Starboard Value holds 8.54M shares of PFE, changed +10.49% as of Jun 30, 2025.
D1 Capital holds 7.62M shares of PFE, changed -2.67% as of Jun 30, 2024.
Orbimed Advisors holds 1.95M shares of PFE, changed +17.76% as of Mar 31, 2026.
Bridgewater Associates holds 1.01M shares of PFE, changed -38.75% as of Jun 30, 2025.
Fairfax Financial holds 990.90K shares of PFE, changed +11.22% as of Mar 31, 2026.

Latest PFE News

Pfizer Advances 25-Valent Vaccine with up to 15x Stronger Immune Response — May 20, 2026
Pfizer gains EU approval for Hympavzi, Phase III shows 93% bleed reduction — May 15, 2026
Pfizer Q1 Revenue Rises 5.7% to $14.5B, Acquisitions Drive $3.1B Growth — May 14, 2026
Pfizer Stock Drops 2.6% Despite Q1 Earnings Beat as Markets Rally — May 8, 2026
Pfizer CEO Backs CDC Nominee Erica Schwartz, Signaling Vaccine Policy Stability — May 6, 2026

PFE Analyst Consensus

22 analysts cover PFE: 0 strong buy, 8 buy, 11 hold, 3 sell, 0 strong sell. Consensus rating is neutral. Average price target: $29.17.

Common questions about PFE

Who owns PFE stock?: Hedge funds tracked by Rallies that own PFE include Starboard Value, D1 Capital, Orbimed Advisors, Bridgewater Associates, and Fairfax Financial. The latest tracked quarter is Jun 30, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Pfizer.
Does Rallies show 13F holders for PFE?: Yes. Rallies tracks hedge fund and 13F ownership data for PFE, including fund names, share counts, latest tracked quarter, and position changes when available.
Is PFE research on Rallies investment advice?: No. Rallies provides research, data, and educational context for PFE. It does not provide personalized investment advice.